Short answer: Aromatase inhibitors, tamoxifen, chemotherapy and ovarian suppression can all cause vaginal dryness after breast cancer. ACOG recommends non-hormonal treatment first, such as lubricants, moisturizers like hyaluronic acid, and vitamin E or D suppositories; low-dose vaginal estrogen may be considered only after discussion with your oncologist.
Vaginal dryness is one of the most common and most distressing side effects of breast cancer treatment, and it’s often under-discussed. Because many survivors are advised to avoid estrogen, finding relief can feel complicated. Here’s what causes it and which options are worth discussing with your care team.
Key takeaways
- Aromatase inhibitors, tamoxifen, chemotherapy and ovarian suppression can all cause vaginal dryness.
- ACOG recommends non-hormonal treatments first: lubricants, moisturizers such as hyaluronic acid, and vitamin E or D suppositories.
- Low-dose vaginal estrogen may be considered if non-hormonal options fail, after discussion with your oncologist.
By the numbers
- A 2018 expert consensus from The Menopause Society and ISSWSH found that genitourinary symptoms are more common in breast cancer survivors, often start earlier because of cancer treatment, and are frequently undiagnosed and untreated (Faubion et al., Menopause, 2018).
Why breast cancer treatment causes dryness
- Aromatase inhibitors (like anastrozole, letrozole and exemestane) lower estrogen levels dramatically, which often causes significant dryness
- Tamoxifen can cause vaginal changes, although its effects vary
- Chemotherapy can trigger early or sudden menopause
- Ovarian suppression or removal quickly lowers estrogen
- Stopping hormone therapy at diagnosis can bring menopause symptoms back
Because these changes can happen suddenly rather than gradually, symptoms are often more intense than with natural menopause.
Vaginal dryness after chemotherapy
Chemotherapy can cause vaginal dryness by interfering with the ovaries. According to the American Cancer Society, some types of chemo can disrupt normal hormone function and bring on early menopause, with symptoms such as vaginal dryness and thinning of the vaginal lining that can make sex uncomfortable [3].
- It may be temporary or permanent. Some younger women see periods and moisture return after treatment; for others, menopause is permanent.
- Hormone-blocking drugs taken after chemo, such as aromatase inhibitors, often make dryness worse.
- Tell your cancer care team. They can only help with problems they know about, and hormone-free options can be started right away.
Non-hormonal options
Vaginal moisturizers
Used regularly, moisturizers are usually the first step. Hyaluronic acid formulas are a common choice.
Lubricants
Use a gentle water- or silicone-based lubricant during intimacy. Silicone lubricants are often preferred for longer-lasting comfort. See how to choose.
Hormone-free serums
Some women prefer hormone-free cosmetic serums that combine hyaluronic acid with peptides or growth factors. If you have a history of cancer, check with your oncology team before starting any new intimate product.
Pelvic floor physical therapy and dilators
When sex has been painful, pelvic muscles can tighten protectively. A pelvic floor physical therapist can help, and vaginal dilators can gently restore comfort and flexibility.
Lidocaine
Some clinicians suggest applying a topical anesthetic to the vaginal opening before intercourse to reduce pain. Ask your doctor before trying this.
Looking for a hormone-free option?
AIRS Advanced Intimate Renewal Serum combines hyaluronic acid with bioengineered growth factors and peptides in single-use applicators. The 90-Day Regimen (3 boxes) is our best value and ships free.
What about vaginal estrogen?
Low-dose vaginal estrogen may be an option for some survivors whose symptoms don’t improve with non-hormonal care, but the decision is individual. It depends on your cancer type, your current medications (especially aromatase inhibitors) and your oncologist’s guidance. Never start hormonal products without talking to your oncology team.
Talking with your care team
Sexual health is part of survivorship care. It’s okay to bring it up, and it’s worth asking for a referral to a menopause specialist, sexual health clinic or pelvic floor therapist if your oncology team can’t help directly.
FAQ
Will vaginal dryness go away after I finish treatment?
It depends. Dryness from chemotherapy-induced menopause or long-term hormone therapy often continues, so ongoing care helps.
Are all lubricants safe for breast cancer survivors?
Most water- and silicone-based lubricants don’t contain hormones. Avoid products with fragrance or warming agents if you’re sensitive, and check labels for hormone ingredients.
What the guidelines say
- ACOG recommends that nonhormonal methods be considered first-line treatment for urogenital symptoms after estrogen-dependent breast cancer, including lubricants, hyaluronic acid and vitamin E or D suppositories [2].
- Low-dose vaginal estrogen may be considered if nonhormonal options fail, after a risk-benefit discussion. For women taking aromatase inhibitors, ACOG advises shared decision-making between the patient, gynecologist and oncologist [2].
- The Menopause Society notes that data on safety in breast cancer survivors are still limited, so treatment should be individualized with your oncologist [1].
Can chemotherapy cause vaginal dryness?
Yes. Some chemotherapy drugs disrupt the ovaries and can bring on early menopause, which lowers estrogen and causes vaginal dryness and thinning. Moisturizers and lubricants can help right away; talk with your cancer care team about other options.
Related reading
- Find a doctor, specialist or support
- Vaginal estrogen vs. hormone-free options
- Alternatives to vaginal estrogen
- Vaginal dryness treatment options compared
- Genitourinary Syndrome of Menopause (GSM) explained
- Hyaluronic acid for vaginal dryness
- Painful sex after menopause
- Medications that cause vaginal dryness
Sources
- American College of Obstetricians and Gynecologists. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer (Clinical Consensus No. 2). Obstet Gynecol. 2021;138:950–960.
- The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement. Menopause. 2020;27(9):976–992.
- American Cancer Society. Hormone therapy, chemo, immunotherapy, and sex (women).



